NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

Austin, Texas, United States, June 6th, 2025, FinanceWire


  • The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics.
  • HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25.
  • Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer.
  • NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality.

NRx Pharmaceuticals NRXP, a clinical-stage biopharmaceutical company, known for treating suicidal bipolar depression and acute suicidal depression, has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute. The Kadima acquisition agreement (not yet closed) is part of HOPE’s strategy to establish a scalable mental health treatment network of interventional psychiatry clinics. (https://ibn.fm/DjOMz).

Kadima, located in La Jolla, California, will become the clinical and operational template for the proposed network. Known for its work in interventional psychiatry, the clinic’s integration with…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP


Contact
IBN
www.InvestorBrandNetwork.com
Editor@InvestorBrandNetwork.com
NRXP Logo
NRXPNRX Pharmaceuticals Inc
$3.6411.4%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
96.28
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...